Next generation gene writing platform to cure genetic and oncological diseases

Introduction

Gene therapy offers a promising opportunity for treating the more than 10,000 human genetic diseases, as well as other disorders, such as cancer, by editing disease-causing genetic defects or engineering immune cells to target cancer cells.

Current Limitations

However, most genetic disorders remain untreatable, as gene therapy still holds untapped potential due to significant limitations of current editing technologies. These limitations include:

• Lack of efficiency
• Lack of precision
• Lack of safety

Thus, these factors present limitations in scope and applicability.

Integra Therapeutics

Integra Therapeutics, a spin-off of the Pompeu Fabra University (UPF), has developed an advanced genome writing platform that overcomes the limitations of current gene editing technologies.

FiCAT Technology

Our proprietary gene writing technology platform, FiCAT, combines the precision of RNA-guided nucleases with the effectiveness of programmable transposases to insert large pieces of DNA in a safe, precise, and stable way.

Key Features of FiCAT

FiCAT has the capacity to integrate virtually any gene into the genome with unprecedented efficiency, precision, and safety.

Validation and Future Potential

FiCAT has already been validated in several ex vivo and in vivo models. With FiCAT, we will unlock the potential of gene writing to cure genetic diseases and bring life-changing therapies to patients suffering from high unmet need genetic and neoplastic diseases.